Role of ADAMs in Endothelial Cell Permeability
Cadherin Shedding and Leukocyte Rolling

Bharathy Ponnuchamy, Raouf A. Khalil

Endothelial cells constitute a selective barrier that controls the passage of plasma proteins and circulating cells from the blood to tissues. This is achieved by the caveolar–vesicular system and by the dynamic opening and closing of intercellular junctions. Interendothelial cell junctions are almost absent in the postcapillary venules, where cellular extravasation and exchange of plasma constituents occur, but are well-organized in the large vessels to ensure strict control of vascular permeability. Cadherins are Ca\textsuperscript{2+}– and protease-sensitive molecules that mediate homotypic cell-to-cell adhesion. Endothelial cells express N-, P-, and VE-cadherin. N-cadherin is diffusely spread on the cell surface, whereas P-cadherin is present in trace amounts. VE-cadherin is a single-chain transmembrane glycoprotein localized at specialized interendothelial cell contact regions referred to as adherens junctions.

Vascular inflammation has been implicated in the development and progression of vascular diseases such as hypertension and atherosclerosis. The inflammatory response is initiated by injury of the endothelium inflicted by factors such as oxidized low-density lipoprotein, reactive oxygen species, and viruses. Endothelial cell injury prompts the recruitment of circulating leukocytes to the injury site, and the disruption of the endothelial cell barrier allows leukocyte infiltration of the vessel wall (Figure). Leukocyte recruitment and infiltration of the vascular wall is a complex process encompassing a series of adhesion and deathadhesion events and distinct adhesion molecules on the activated endothelium and leukocytes.

Cadherin Shedding and Leukocyte Rolling
An important mechanism regulating leukocyte recruitment to the vascular wall involves the proteolytic cleavage of adhesion molecules by cell-associated metalloproteases, a process called “shedding.” The shedding process can be exemplified in the adhesion protein selectin. Leukocyte (L)-selectin acts as a homing receptor for the targeting and initial interaction between leukocytes and activated endothelium, a process called “rolling.” Endothelial (E)-selectin and platelet (P)-selectin are stored intracellularly, but, when the cells are activated, they translocate to the cell surface, where they participate in the initial rolling of leukocytes over the activated endothelium. Focal shedding of endothelial E-selectin is thought to promote leukocyte infiltration and lesion formation. Also, blood levels of soluble vascular cell adhesion molecule-1 and intracellular adhesion molecule-1 are increased in atherosclerosis, suggesting their shedding during lesion development. Additionally, inflammatory mediators such as thrombin cause proteolysis of VE-cadherin, thereby disrupting the organization of endothelial adherens junctions and increasing vascular permeability and edema. The role of VE-cadherin shedding in endothelial cell permeability is further supported by reports that induction of apoptosis in human umbilical vein endothelial cells is associated with dissolution of adherens junctions, loss of cell–cell contacts, and shedding of VE-cadherin. Although factors associated with the expression of transmembrane adhesion molecules and their dysregulation in atherosclerosis have been studied, the mechanisms involved in the release of these adhesion molecules from the cell surface by controlled cleavage or shedding are not well-understood.

Role of ADAMs as Adhesion Molecule Sheddases
Disintegrin and metalloproteases (ADAMs) are membrane-anchored glycoproteins and regulatory enzymes that have been implicated in cell adhesion as well as the proteolytic conversion or shedding of membrane-bound proteins to soluble forms. ADAMs, like matrix metalloproteinases (MMPs), are members of the metzincin zinc-dependent metalloprotease superfamily. At least thirty members of the ADAMs protein family share a common structure consisting of a prodomain, a metalloprotease domain, a disintegrin domain, a cysteine-rich domain, an epidermal growth factor–like domain, a transmembrane domain, and a cytoplasmic domain. Adams are involved in diverse biological functions including fertilization, neurogenesis, and angiogenesis as well as disease states such as cancer. Adam-17 (tumor necrosis factor–converting enzyme or TACE) was the first member of the ADAM family, with a defined role as a shedding that releases tumor necrosis factor-α and its receptors from neutrophils and macrophages during inflammation. ADAM-1, -12, -15, and -17 have been identified in vascular smooth muscle cells, and ADAM-10, -15, and -17 may have potential roles in the regulation of endothelial function via their metalloprotease and proteolytic properties. Also, the adhesive disintegrin domain of ADAMs allows them to interact with integrins. For example, ADAM-15 may be involved in endothelial–leukocyte or endothelial–tumor adhesion by binding to the classic RGD-
binding integrins $\alpha_\beta_1$ and $\alpha_\beta_2$. The binding of ADAM-12 and -15 disintegrin domains to non-RGD-type integrin $\alpha_\beta_1$ may also mediate cell–cell interaction.16

ADAM-10 and -17 are upregulated in activated endothelium and play a role in ectodomain shedding of adhesion molecules during leukocyte recruitment (Figure).17 Also, fractalkine (CX3CL1) and CXCL16 are adhesion molecules that are upregulated in activated endothelium and macrophages and take part in the initial capture of inflammatory cells. ADAM-10 or -17 cleaves these adhesion molecules to soluble chemoattractant cytokines or chemokines to attract additional inflammatory cells expressing chemokine receptors CX3CR1 and CXCR6.18,19 Also, CD44, another adhesion molecule in inflammatory cells, cross-links to endothelial cell hyaluronan and initiates intracellular signaling cascade, leading to activation of ADAM-10 or -17 and cleavage of the soluble ectodomain of CD44. Soluble CD44 fragments, in turn, compete for uncleaved hyaluronan and promote leukocyte deadhesion and rolling.20 Thus, ADAM-induced release of the soluble ectodomain from the adhesion molecules L-selectin, vascular cell adhesion molecule, intracellular adhesion molecule, fractalkine, CXCL16, and CD44 contribute to leukocyte deadhesion and rolling on activated endothelial cells and their migration to the interendothelial junction.4,21,22

**ADAMs and Vascular Permeability**

ADAM-mediated shedding of cell surface molecules is emerging as a critical pathway not only in the regulation of leukocyte recruitment but also in the control of vascular and nonvascular cell–cell interactions. ADAM-15 is upregulated in atherosclerotic lesions suggesting that ADAMs participate in lesion formation. Also, ADAM-10 is localized in the membrane of epithelial cells of benign glands, suggesting a role in cell–cell, cell–matrix, and cell–basement membrane interactions. Although ADAM-10 does not interact directly with integrins, it may indirectly influence integrin-related adhesion activity by cleaving the L1 membrane adhesion molecule, a type 1 membrane glycoprotein implicated in the migration of neural and tumor cells.23 Also, in resting cells, calmodulin constitutively associates with the pro–ADAM-10 inactive form. An increase in endothelial cell [Ca$^{2+}$]i in response to activators such as thrombin or subsequent to leukocyte adhesion would promote the dissociation of calmodulin and the activation of ADAM-10 (Figure).20,24 However, the molecular mechanisms by which activated ADAM-10 could affect endothelial cell permeability and leukocyte infiltration are not clear.

In this issue of Circulation Research, Schulz et al25 describe the effects of ADAM-10 on permeability of human umbilical vein endothelial cells and T-cell transmigration. They found that ADAM-10 cleaves VE-cadherin ectodomain into a soluble fragment and that the remaining carboxy-terminal membrane–bound stub is further cleaved by $\gamma$-secretase. ADAM-10–mediated cleavage of VE-cadherin is induced by thrombin activation of endothelial cells, Ca$^{2+}$ influx, and induction of apoptosis by staurosporine treatment. Inhibition of ADAM-10 by GI254023X decreased endothelial cell permeability and transmigration of T cells. Also, transfecting T cells with ADAM-10 small interfering RNA caused a decrease in the rate of transmigration of activated T cells. These elegant studies highlight the importance of ADAM-10 in VE-cadherin removal from endothelial cell surface by controlled cleavage or shedding, a potential regulatory pathway of vascular permeability and the inflammation process associated with atherosclerosis.26

**Extracellular Proteases and Intracellular Kinases**

The identification of the role of ADAM-10 in VE-cadherin shedding poses several challenging questions. An important question is whether the observed effects on endothelial adhesion molecules and cell permeability are unique to ADAM-10 or involve cooperative interactions with other ADAMs. For instance, shedding of vascular cell adhesion...
molecule-1 can be mediated by ADAM-17.\textsuperscript{21} Also, binding of ADAM-28 to P-selectin glycoprotein ligand-1 enhances P-selectin–mediated leukocyte adhesion to endothelial cells.\textsuperscript{27} Additionally, ADAM-15 is an adherens junction molecule whose surface expression can be driven by VE-cadherin.\textsuperscript{28}

Because ADAMs have multidomain structure, they are potentially multifunctional with multiple roles depending on their cellular localization. Also, ADAMs may function in concert with other metalloprotease superfamilies such as ADAMTS and MMPs. ADAMTS (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs) include at least 19 members evolved as nonintegral membrane proteins associated with the cell surface and extracellular matrix through specific protein domains. Interestingly, thrombin, an activator of ADAM-10, as well as plasmin promote proteolytic inactivation of ADAMTS-13.\textsuperscript{29} Also, ADAMs may have substrate overlap with MMPs and thereby influence the degradation of extracellular matrix components. This is supported by reports that purified bovine ADAM-10 cleaves native type IV collagen, a major component of the basement membrane and extracellular matrix.\textsuperscript{50} MMPs are also known to activate each other.\textsuperscript{31} Therefore, the potential interactions between ADAMs and MMPs on endothelial cell permeability need to be examined. In this regard, it is important to investigate the effects of inhibitors of ADAMs and MMPs on leukocyte infiltration. Tissue inhibitors of MMPs (TIMPs) are being considered for targeting specific MMPs in localized vascular diseases such as abdominal aortic aneurysm. However, the isolated N-terminal domains of TIMP-1 and TIMP-3 may not be sufficient for ADAM-10 inhibition,\textsuperscript{32} and specific small interfering RNA may provide a more specific approach.

ADAM-induced proteolysis can also change the activity of remnant surface molecular complexes, which, in turn, affect signaling pathways inside the cell. Although the effects of thrombin can be related to increased Ca\textsuperscript{2+} influx in endothelial cells, the role of localized Ca\textsuperscript{2+} gradients and the relation between the intracellular Ca\textsuperscript{2+} stores and other Ca\textsuperscript{2+} regulatory pathways in the surface membrane pumps and exchangers need to be further characterized. Also, whereas an increase in endothelial cell [Ca\textsuperscript{2+]cytosol}, could activate ADAM-10, the proteolytic fragments generated from this reaction may affect the activity of the same or other membrane channels. For instance, studies have suggested an effect of MMPs on membrane Ca\textsuperscript{2+]cytosol} and/or K\textsuperscript{+} channel activity, possibly through an interaction with membrane α3β3 integrin.\textsuperscript{33–36}

An important question also relates to the cellular remnants of cadherin shedding. β-Catenin links the cytoplasmic domain of VE-cadherin to the actin cytoskeleton via α-catenin and therefore contributes to establishing VE-cadherin–mediated cell–cell adhesion (Figure). Ca\textsuperscript{2+} influx and ADAMs activation not only induce the proteolysis of extracellular VE-cadherin, and separation of cell–cell adhesion, but also facilitate the degradation of cytoplasmic domain of VE-cadherin by γ-secretase, resulting in translocation of β-catenin from the plasma membrane to the cytoplasm, where it may alter cell morphology, motility and proliferation.\textsuperscript{37} In addition to Ca\textsuperscript{2+}, the role of Rho kinase and protein kinase C (PKC) in proteolytic dissolution and shedding of adhesion molecules should be considered. Activation of PKC-α may increase endothelial cell permeability by disassembly of VE-cadherin junctions.\textsuperscript{38} Also, vascular endothelial growth factor upregulates the expression of ADAMTS1 through PKC signaling.\textsuperscript{39} Whereas ADAM-10 is a weak substrate of PKC,\textsuperscript{40} phorbol esters activating PKC and the small GTPase Rac can activate ADAM-17–dependent shedding of a variety of substrates.\textsuperscript{21} Thus the discovery of the role of specific ADAMs in VE-cadherin shedding paves the way for further investigations to identify the potential interactions of ADAMs with other adhesion molecules, transmembrane and extracellular metalloproteases, as well as intracellular ion and protein kinase–dependent regulatory pathways. The identification of the mechanisms of cleavage of adhesion molecules by various metalloproteases during vascular lesion formation provides novel leads for the development of therapeutic interventions in vascular diseases.

### Sources of Funding

Supported by National Heart, Lung, and Blood Institute grants HL65998 and HL70659.

### Disclosures

None.

### References


**KEY WORDS:** disintegrin • metalloproteinase • cell adhesion • endothelium • vascular
Role of ADAMs in Endothelial Cell Permeability: Cadherin Shedding and Leukocyte Rolling
Bharathy Ponnuchamy and Raouf A. Khalil

Circ Res. 2008;102:1139-1142
doi: 10.1161/CIRCRESAHA.108.177394
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circres.ahajournals.org/content/102/10/1139

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/